Explore

TrendlineTrendline
AbbVie Seeks Director for Area Market Access Strategy Marketing in Mettawa, IL

AbbVie Seeks Director for Area Market Access Strategy Marketing in Mettawa, IL

AbbVie Seeks Director for Area Market Access Strategy Marketing in Mettawa, IL
TrendlineTrendline
Galderma Seeks Field Access Manager for Dermatology Market in Great Lakes, St. Louis, Memphis Regions

Galderma Seeks Field Access Manager for Dermatology Market in Great Lakes, St. Louis, Memphis Regions

Galderma Seeks Field Access Manager for Dermatology Market in Great Lakes, St. Louis, Memphis Regions
USA TodayUSA Today
How Mark Cuban's drug prices compare to corporate-owned pharmacies

How Mark Cuban's drug prices compare to corporate-owned pharmacies

Employers increasingly are scrutinizing pharmacy benefit managers and overall spending on drugs. A study finds Mark Cuban's pharmacy might be a fix.
AP NewsAP News
FDA says its safety review of abortion pill will continue into next year

FDA says its safety review of abortion pill will continue into next year

The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year
Rapid ReadRapid Read
Wegovy Demonstrates 20% Reduction in Cardiovascular Events, Zepbound Shows Greater Weight Loss in Direct Comparison

Wegovy Demonstrates 20% Reduction in Cardiovascular Events, Zepbound Shows Greater Weight Loss in Direct Comparison

A recent analysis comparing GLP-1 receptor agonists Wegovy (semaglutide) and Zepbound (tirzepatide) highlights distinct advantages for each medication. Wegovy has demonstrated a 20% relative reduction in major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with established heart disease and overweight or obesity, based on the SELECT trial. This makes Wegovy the only one of the two with randomized proof of such cardiovascular benefits. In contrast, Zepbound has shown superior average weight loss. The SURMOUNT-5 trial, a direct head-to-head comparison, found that participants on tirzepatide (Zepbound) lost an average of 20.2% of their starting body weight over 72 weeks, compared to 13.7% for those on semaglutide (Wegovy). Both drugs are approved for chronic weight management and share common gastrointestinal side effects like nausea, diarrhea, and vomiting. The choice between them depends on individual health history and specific treatment goals, such as pr...
TrendlineTrendline
Bay Area Biotech Companies Drive Innovation Across Diverse Therapeutic Areas

Bay Area Biotech Companies Drive Innovation Across Diverse Therapeutic Areas

Bay Area Biotech Companies Drive Innovation Across Diverse Therapeutic Areas
Rapid ReadRapid Read
FDA Issues Recalls and Warnings for Various Drugs, Including Amazon Acetaminophen and Compounded Glutathione

FDA Issues Recalls and Warnings for Various Drugs, Including Amazon Acetaminophen and Compounded Glutathione

The FDA has issued several drug recalls and warnings, highlighting concerns over manufacturing practices, product quality, and potential health risks. Among the recalled products are Amazon Acetaminophen Extra Strength Caplets, due to consumer complaints of discolored tablets, and compounded glutathione from Greenwich Rx Compounding Pharmacy, which is under recall for potential elevated endotoxin levels. Other recalls include Benzoyl Peroxide Wash for microbial contamination, Clindamycin Phosphate Foam for defective containers, and Estradiol Gel for empty or partially filled packets. Additionally, FOCUS PI Hypromellose eye drops and K.C. Pharma's various eye drop brands are being recalled due to a lack of assurance of sterility. The FDA also issued warnings regarding unapproved skin-lightening creams, Orbi 20 Whitening Cream and Omni Gold Anti-Marks Cream, found to be contaminated with mercury. These actions are part of the FDA's ongoing efforts to ensure drug safety and compliance with federal regulations...
Rapid ReadRapid Read
HRSA Approves Initial 340B Rebate Pilot Plans from Pharmaceutical Manufacturers

HRSA Approves Initial 340B Rebate Pilot Plans from Pharmaceutical Manufacturers

The Health Resources and Services Administration (HRSA) has approved rebate model plans from 10 pharmaceutical manufacturers for the 340B Drug Pricing Program. These approvals, announced on October 1, cover 18 out of 20 products potentially eligible for rebate models in 2027. Eligibility for these rebates is contingent on Medicare payment for the products being negotiated through the Medicare Drug Price Negotiation Program in 2027. Notably, AstraZeneca declined to submit a plan for its cancer drug Calquence, and Novo Nordisk did not submit plans for Ozempic and its related products before the September deadline. Additionally, four other products are no longer eligible for negotiation due to statutory provisions concerning market competition and the availability of generic or biosimilar equivalents. Pharmaceutical manufacturer Bausch exited the 340B program in 2025, rendering its products ineligible for Medicaid or Medicare reimbursement. HRSA has also updated its rebate model webpage with FAQs and details ...
Rapid ReadRapid Read
Life Insurers Label Active Surveillance for Prostate Cancer as 'Untreated Cancer,' Impacting Coverage

Life Insurers Label Active Surveillance for Prostate Cancer as 'Untreated Cancer,' Impacting Coverage

Individuals undergoing active surveillance for low-risk prostate cancer are facing significant challenges in securing life insurance, as insurers often categorize their condition as 'untreated cancer.' This issue, highlighted by a medical journalist who experienced rejections from eight insurers in 2013, persists today. Despite medical recommendations for active surveillance—close monitoring with PSA blood tests, biopsies, and MRIs for low-risk cases like Gleason 6 (Grade Group 1)—insurance underwriters view this approach differently. A hypothetical case of a 64-year-old man with a new Gleason 6 diagnosis and a past heart attack, referred to as 'Young Howard,' revealed that insurers might postpone decisions for three to five years, requiring stable PSA results and no upgrading. This delay, coupled with potential higher rates due to age and other health factors like a heart attack, creates substantial financial penalties for patients following their doctors' advice.
Rapid ReadRapid Read
AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

Artificial intelligence is revolutionizing clinical trials by significantly improving the speed, standardization, and objectivity of medical imaging analysis. Traditionally, radiologists manually review images like MRI, CT, and PET scans, a process that is time-consuming and prone to variability. AI-driven tools, utilizing deep learning and computer vision, can detect subtle changes in disease progression that are often difficult for humans to quantify. This advancement is leading to faster decision-making in drug development, with industry reports indicating AI can accelerate imaging review timelines by up to 50%. Regulatory agencies are increasingly receptive to AI in clinical trials, provided the tools are properly validated, as AI provides clear, quantifiable evidence crucial for submissions. Beyond imaging, AI is also being used to broaden clinical trial screening and is integrated into adaptive clinical trial designs. The FDA has established the Office of Innovation and Clinical Trial Modernization t...
Rapid ReadRapid Read
Cancer Survival Rates: The Complex Meaning of the 'Five-Year Mark' in Oncology

Cancer Survival Rates: The Complex Meaning of the 'Five-Year Mark' in Oncology

The 'five-year survival' statistic in cancer treatment is a benchmark used by doctors and researchers, but it does not equate to a 'five-year cure.' While over 10 million cancer survivors in the U.S. have lived beyond five years, and more than 1.4 million beyond 20 years, the meaning of this milestone varies significantly depending on the type of cancer. For solid tumors like breast, colorectal, and prostate cancers, which have longer cellular doubling times, microscopic cells can hide and evade detection, making long-term behavior harder to predict. In contrast, cancers with short doubling times, such as testicular cancer, may be considered cured after a few years if no recurrence is detected. The National Cancer Institute (NCI) emphasizes that while five years is an important landmark, it does not guarantee a cure and patients may still face long-term effects or secondary cancers.
ReutersReuters
Pharmaceutical lobby sues Trump administration over most-favored-nation pricing

Pharmaceutical lobby sues Trump administration over most-favored-nation pricing

By Michael Erman Oct 7 (Reuters) - The pharmaceutical industry's top lobby group on Wednesday sued to invalidate one piece of the Trump administration's efforts to benchmark US drug prices to lower costs overseas in the Medicare health insurance program, arguing that it is an illegal overreach by